Pandemic Perspectives: Riding The Waves Of Asia’s Healthtech Innovation Explosion
A VC Investor’s view of healthtech developments during COVID-19 and beyond in the markets that account for 60% of the global population
One year on, we’ve seen how the coronavirus prompted entrepreneurial instincts to surface in the medtech and healthtech sectors. Asia healthtech investor specialist HealthXCapital tells Medtech Insight about the changes that are likely to stick as in an industry that has seen the value of rapid responsiveness to acute need.
You may also be interested in...
The pandemic has shaken up investor priorities and changed the outlook for health care start-ups – or has it? Nooman Haque managing director, life sciences and healthcare at Silicon Valley Bank, gives his view of what has changed over the past year, and looks at future trends.
The final list of medical devices and IVDs classifies products according to India’s imminent new rules for medtech products. It contains about 100 fewer entries than the original draft issued in June.
Singapore drives much of the medtech regulatory and policy thought leadership in the ASEAN region, as shown in its regulatory collaboration with Thailand and actions on cybersecurity and packaging waste.